Mirena 52 MG systems
Ended Awarded Last action
- Contract number
- SPE2DR26FCHU7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,630
Award facts
- Contract value 100% obligated
- $10,629.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded on December 12, 2025, by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, provides for the supply of Mirena 52 mg contraceptive systems. The contract is issued under a firm fixed-price arrangement with a ceiling value of $10,629.60 and an ultimate completion date of January 6, 2026. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This delivery order is issued under the company's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. holds contract SPE2DR under the PPV-G GEN V program, which was awarded on November 13, 2025, with a $500 million ceiling and extends through December 31, 2036, encompassing a 30-month base period and three 30-month option periods. The company's established performance across diverse pharmaceutical product categories—including specialty pharmaceuticals, biologics, vaccines, and medical consumables—positions it as a critical supplier within the federal pharmaceutical supply chain. As one of multiple regional prime vendor contractors under this broader DLA initiative, DMS Pharmaceutical Group supplies recurring medical requirements to support military healthcare operations globally through firm fixed-price delivery orders.
Quick answers
Who was awarded contract SPE2DR26FCHU7?
SPE2DR26FCHU7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FCHU7 worth?
The government has obligated $10,630 on SPE2DR26FCHU7.
Is contract SPE2DR26FCHU7 an order under another contract?
Yes. SPE2DR26FCHU7 is a delivery order under SPE2DR25D9113, an indefinite delivery contract.
Was contract SPE2DR26FCHU7 competed?
The extent of competition for SPE2DR26FCHU7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award